We are live on
!
Find out more
ECM
Endurant Capital Management Portfolio holdings
AUM
$17.4M
1-Year Est. Return
7.38%
This Fund
S&P 500
This Quarter
Est. Return
+7.56%
1 Year Est. Return
+7.38%
3 Year Est. Return
+18.38%
5 Year Est. Return
+100.61%
10 Year Est. Return
–
AUM
$115M
AUM Growth
-$80.1M
(-41%)
Cap. Flow
-$107M
Cap. Flow
% of AUM
-93.27%
Top 10 Holdings %
Top 10 Hldgs %
68.73%
Holding
65
New
15
Increased
2
Reduced
17
Closed
31
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agilent Technologies
A
|
+$5.83M |
| 2 |
IQVIA
IQV
|
+$3.85M |
| 3 |
Boston Scientific
BSX
|
+$3.19M |
| 4 |
Cardinal Health
CAH
|
+$2.68M |
| 5 |
Medtronic
MDT
|
+$2.34M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BioMarin Pharmaceuticals
BMRN
|
+$20M |
| 2 |
Becton Dickinson
BDX
|
+$16.1M |
| 3 |
Elevance Health
ELV
|
+$14.6M |
| 4 |
Sabra Healthcare REIT
SBRA
|
+$13.4M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$6.18M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 66.02% |
| 2 | Real Estate | 1.72% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
Cartesian Therapeutics
RNAC
$229M
| $768K | 0.67% |
22,871
-49,340
| -68% | -$1.77M |
|
|
ADAP
27
DELISTED
Adaptimmune Therapeutics
ADAP
| $759K | 0.66% |
821,038
-839,797
| -51% | -$1M |
|
28
Acadia Healthcare
ACHC
$2.82B
| $729K | 0.64% |
+9,153
| New | +$661K |
|
|
ETNB
29
DELISTED
89bio
ETNB
| $555K | 0.48% |
29,282
+9,697
| +50% | +$170K |
|
30
OrthoPediatrics
KIDS
$535M
| $471K | 0.41% |
+10,741
| New | +$495K |
|
|
MASI
31
DELISTED
Masimo
MASI
| $469K | 0.41% |
+2,850
| New | +$496K |
|
32
CALL
BioXcel Therapeutics
BTAI
$26.5M
| $380K | 0.33% |
+3,569
| New | +$1.19M |
|
33
Olema Pharmaceuticals
OLMA
$984M
| $363K | 0.32% |
+40,184
| New | +$243K |
|
34
Viking Therapeutics
VKTX
$3.78B
| $336K | 0.29% |
20,754
-36,289
| -64% | -$760K |
|
35
Aclaris Therapeutics
ACRS
$743M
| – | – |
-83,891
| Closed | -$679K |
|
|
ADXN
36
Addex Therapeutics
ADXN
$6.58M
| – | – |
-6,037
| Closed | -$114K |
|
37
Avantor
AVTR
$9.23B
| – | – |
-225,615
| Closed | -$4.77M |
|
38
Baxter International
BAX
$14.5B
| – | – |
-34,508
| Closed | -$1.4M |
|
39
Biodesix
BDSX
$231M
| – | – |
-5,663
| Closed | -$211K |
|
40
Bio-Rad Laboratories Class A
BIO
$8.96B
| – | – |
-9,185
| Closed | -$4.4M |
|
|
41
BioXcel Therapeutics
BTAI
$26.5M
| – | – |
-728
| Closed | -$242K |
|
42
Coherus Oncology
CHRS
$222M
| – | – |
-64,956
| Closed | -$444K |
|
43
Centene
CNC
$31B
| – | – |
-29,586
| Closed | -$1.87M |
|
44
Cencora
COR
$60.3B
| – | – |
-9,153
| Closed | -$1.47M |
|
45
Healthpeak Properties
DOC
$15B
| – | – |
-100,685
| Closed | -$2.21M |
|
46
DexCom
DXCM
$32.8B
| – | – |
-22,185
| Closed | -$2.58M |
|
47
Icon
ICLR
$12.3B
| – | – |
-26,830
| Closed | -$5.73M |
|
48
Iovance Biotherapeutics
IOVA
$1.92B
| – | – |
-80,455
| Closed | -$492K |
|
49
McKesson
MCK
$99.6B
| – | – |
-7,312
| Closed | -$2.6M |
|
50
Moderna
MRNA
$22.1B
| – | – |
-36,130
| Closed | -$5.55M |
|
Similar funds
VAFP
CA
SCM
FWM
TOPU
CCMU
TGI
HSCU
Endurant Capital Management's Q2 2023 Portfolio in Review
As of Q2 2023, Endurant Capital Management held 65 positions worth $115M, down 41% from $195M the previous quarter. Its ten largest holdings account for 69% of the portfolio.
Endurant Capital Management withdrew a net $107M in Q2 2023, closing 31 positions and reducing 17 holdings. Its most notable exit was Sabra Healthcare REIT, an estimated $13.4M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 66% of assets, down from 92% a quarter earlier, followed by Real Estate.
Against the trend, Endurant Capital Management opened a new position in Agilent Technologies worth $5.5M.
- Endurant Capital Management's largest Q2 2023 buy was Agilent Technologies: 45,762 shares worth $5.5M.
- Endurant Capital Management added most to Encompass Health in Q2 2023, an estimated $391K increase.
- Endurant Capital Management's biggest Q2 2023 reduction was BioMarin Pharmaceuticals, cutting an estimated $20M.
- Endurant Capital Management fully exited Sabra Healthcare REIT in Q2 2023, selling an estimated $13.4M.
- Endurant Capital Management's ten largest holdings make up 69% of its $115M portfolio in Q2 2023.
- Endurant Capital Management opened 15 new positions and closed 31 in Q2 2023.
- Endurant Capital Management's portfolio value fell 41% quarter-over-quarter to $115M.
Based on Endurant Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.